Abbott’s multipurpose disinfecting solution for contacts gets FDA OK
ABBOTT PARK, Ill. Abbott has received market clearance from the Food and Drug Administration for RevitaLens Ocutec, a multipurpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.
"This advanced, next-generation solution establishes a new standard of disinfecting technology for contact lens wearers," stated Jim Mazzo, SVP Abbott Medical Optics. "Proper contact lens care, including a rub and rinse regimen using RevitaLens Ocutec, will help patients achieve clean and comfortable lenses while enhancing overall lens-wearing satisfaction."
RevitaLens Ocutec multipurpose disinfecting solution was developed in cooperation with silicone hydrogel, microbiology and chemistry experts and with input from more than 600 eye care professionals.
It is estimated that there are 125 million contact lens wearers worldwide. Multipurpose solutions represent the majority of systems used for the care of soft contact lenses. These are comprised of a single solution for the rinsing, cleaning, disinfection and storage of lenses, and typically are composed of a preservative, buffer system and other agents to aid in lens cleaning and comfort.
Key characteristics of RevitaLens Ocutec multipurpose disinfecting solution include:
- High micro-organism kill rates;
- Removes proteins from the lens surface;
- Effectively kills acanthamoeba and fusarium;
- Reduces corneal staining; and
- Minimizes the risk of eye complications.
Abbott plans to begin retail shipment of RevitaLens Ocutec multipurpose disinfecting solution in the United States in October. The product also has CE Mark approval in Europe.
Decision Resources: Generic competition will crush hypertension drug market
BURLINGTON, Mass. The market for hypertension drugs will drop by $3 billion by the end of the decade due to generic competition, according to a new report by healthcare market research firm Decision Resources.
The report, announced Tuesday, found that the market for drugs to treat high blood pressure would decline from 2009’s $26 billion to $23 billion by 2019 in the United States, United Kingdom, France, Italy, Spain and Japan.
The largest decline will hit Novartis’ Diovan (valsartan), which will lose more than $1 billion in sales in 2013, following market entry of generic versions of the drug.
“Emerging agents will find it difficult to penetrate the highly genericized hypertension market because of competition from inexpensive and efficacious generic anti-hypertensive drugs,” Decision Resources analyst Taskin Ahmed said. “Through 2019, we do not forecast blockbuster sales for any of the emerging anti-hypertensive agents.”
Baptist Healthcare System wants more Walmart clinics
LOUISVILLE, Ky. Baptist Healthcare System, which operates a network of hospitals and other facilities throughout the state, is looking to expand the number of clinics it operates inside select Walmart locations, according to a local news report.
Baptist Healthcare System currently operates six Baptist Express Care clinics at six Walmart stores in the state.
According to Business First of Louisville, the healthcare system is looking to open 24 clinics in such areas as Middletown and Shelbyville, Nicholasville and Somerset, Ky.
"I really see these as a piece of the puzzle for healthcare reform that really has not been developed as far as it needs to be yet," Tim Marcum, director of planning for Baptist Hospital East, was quoted as saying in Business First of Louisville. "We’re trying to go along that route."